Bright Uro Sees First Glean Urodynamics Adoption Within U.S. Urology Partners Network

According to a recent LinkedIn post from Bright Uro, New Jersey Urology, a Summit Health company, has completed its first procedures using the Glean urodynamics system, becoming the first practice within U.S. Urology Partners to adopt the technology. The post presents this as a milestone in enabling urodynamic studies across multiple clinic locations rather than concentrating testing at a single site.

The LinkedIn post quotes Dr. David Sussman, who suggests that Glean allows urodynamics to be offered at every clinic and helps close a diagnostic gap in male lower urinary tract symptoms. For investors, this early clinical utilization at a large urology group may indicate initial commercial traction, validate demand for more distributed urodynamics capabilities, and potentially support Bright Uro’s growth prospects if wider network adoption within U.S. Urology Partners and similar groups follows.

The expansion of access across locations could also highlight Glean’s operational advantages, such as portability or workflow efficiency, which may be important differentiators in purchasing decisions by large practice groups. If replicated at scale, broader deployment in multi-site urology practices could translate into recurring device and consumable revenue, strengthening Bright Uro’s position in the urodynamics market and enhancing its value proposition ahead of any future financing or strategic transactions.